Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.
M. W. Jones
No relevant relationships to disclose
C. Zhang
No relevant relationships to disclose
K. R. Oettel
No relevant relationships to disclose
J. H. Blank
No relevant relationships to disclose
E. G. Robinson
No relevant relationships to disclose
H. G. Ahuja
No relevant relationships to disclose
R. J. Kirschling
No relevant relationships to disclose
P. H. Johnson
No relevant relationships to disclose
M. S. Huie
No relevant relationships to disclose
J. Kolesar
No relevant relationships to disclose
M. B. Wims
No relevant relationships to disclose
H. Hernan
No relevant relationships to disclose
T. C. Campbell
No relevant relationships to disclose
A. M. Traynor
No relevant relationships to disclose
T. Hoang
No relevant relationships to disclose